Market closedNon-fractional
Taro/TARO
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Taro
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Ticker
TARO
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
Headquarters
Haifa, Israel
Employees
1,554
Website
www.taro.com
Taro Metrics
BasicAdvanced
$1.6B
Market cap
29.88
P/E ratio
$1.43
EPS
0.56
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
0.56
52-week high
$45.76
52-week low
$32.67
Average daily volume
0.66
Financial strength
Current ratio
3.609
Quick ratio
3.042
Enterprise value to free cash flow
23.747
Management effectiveness
Return on assets (TTM)
2.51%
Return on equity (TTM)
3.06%
Return on investment (TTM)
3.03%
Valuation
Price to earnings (TTM)
29.878
Price to revenue (TTM)
2.558
Price to book
0.898
Price to tangible book (TTM)
0.906
Price to free cash flow (TTM)
22.881
Growth
Revenue change (TTM)
9.81%
Earnings per share change (TTM)
111.70%
3-year revenue growth
4.65%
What the Analysts think about Taro
Analyst Ratings
Majority rating from 1 analysts.
Taro Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$165M
4.96%
Net income
$15M
-25.74%
Profit margin
9.09%
-29.26%
Taro Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 24
Actual
$0.54
Expected
$0.30
Surprise
80.00%
Taro News
AllArticlesVideos
![Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger](https://cdn.snapi.dev/images/v1/h/r/press3-2418139.jpg)
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
Business Wire·2 months ago
![TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO](https://cdn.snapi.dev/images/v1/g/8/press8-2384140.jpg)
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
Business Wire·2 months ago
![Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.](https://cdn.snapi.dev/images/v1/d/b/press2-2371253.jpg)
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taro stock?
Taro (TARO) has a market cap of $1.6B as of July 05, 2024.
What is the P/E ratio for Taro stock?
The price to earnings (P/E) ratio for Taro (TARO) stock is 29.88 as of July 05, 2024.
Does Taro stock pay dividends?
No, Taro (TARO) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Taro dividend payment date?
Taro (TARO) stock does not pay dividends to its shareholders.
What is the beta indicator for Taro?
Taro (TARO) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Taro stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Taro stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.